<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03755752</url>
  </required_header>
  <id_info>
    <org_study_id>17300250</org_study_id>
    <nct_id>NCT03755752</nct_id>
  </id_info>
  <brief_title>Safety of Trypan Blue on Endothelium of Diabetic Retinopathy Patients</brief_title>
  <official_title>Safety of Trypan Blue Capsule Staining to Corneal Endothelium in Patients With Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the use of Trypan Blue staining of the corneal endothelium in patients
      undergoing phacoemulsification. It is a single-center prospective, randomized individual
      cohort study. One eye in each patient with diabetic retinopathy will undergo
      phacoemulsification without Trypan Blue capsule staining (control eye) while the other eye
      will undergo phacoemulsification with Trypan Blue capsule staining (study eye). Both eyes
      will undergo intraocular lens implantation. Preoperative and four-week postoperative
      quantitative and qualitative morphometric endothelial cell analyses of the cornea will be
      performed using noncontact specular microscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Randomization was done using an envelope technique wherein, after each patient was placed on the operating bed, the surgeon opened the patient's corresponding envelope, which contained information about whether Trypan Blue should be used for anterior capsular staining or not.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial cell density</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell coefficient of variation</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of hexagonal cells</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corneal thickness</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Cataract Diabetic</condition>
  <arm_group>
    <arm_group_label>Phacoemulsification with Trypan Blue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phacoemulsification with Trypan Blue capsule staining of the anterior lens capsule in patients with diabetic retinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phacoemulsification without Trypan Blue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phacoemulsification without Trypan Blue capsule staining of the anterior lens capsule in patients with</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacoemulsification with and without Trypan Blue capsule staining</intervention_name>
    <description>Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.</description>
    <arm_group_label>Phacoemulsification with Trypan Blue</arm_group_label>
    <arm_group_label>Phacoemulsification without Trypan Blue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with bilateral cataract and diabetic retinopathy

        Exclusion Criteria:

          -  History of ocular surgery Active

          -  ocular inflammation Corneal opacities

          -  Pseudoexfoliation syndrome

          -  Anterior chamber flare and (or) other signs of possibly altered blood - queous barrier

          -  Iris neovascularization (rubeosis)

          -  Uncontrolled glaucoma

          -  Congenital or traumatic cataracts

          -  History or present chronic use of topical or systemic steroids

          -  Poor papillary dilatation (&lt;6 mm)

          -  Specular microscopy cell density &lt; 2000 cell/mm2

          -  Patients who experienced complications fromphacoemulsification
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>November 26, 2018</last_update_submitted>
  <last_update_submitted_qc>November 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Khaled Abdelazeem</investigator_full_name>
    <investigator_title>Lecturer of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diminazene aceturate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

